Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of Tremelimumab for Patients with Unresectable Malignant Mesothelioma

Investigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a disease called unresectable malignant mesothelioma, which affects the lining of the lungs or abdomen. The study is testing a treatment called Tremelimumab, which is given as a solution through an infusion, meaning it is delivered directly into the bloodstream. The trial will compare the effects of Tremelimumab to a placebo, which is a substance with no active medication, to see if Tremelimumab can help improve the survival of patients with this type of mesothelioma.

The purpose of the study is to understand if Tremelimumab can help people live longer when they have this type of cancer that cannot be removed by surgery. Participants in the study will receive either Tremelimumab or a placebo, and their health will be monitored over time to see how they respond to the treatment. The study will last for a period of up to 36 months, during which participants will have regular check-ups and tests to track their progress and any side effects they might experience.

Throughout the study, researchers will also look at other important factors, such as how the treatment affects the quality of life and any potential side effects. The study aims to provide valuable information about the safety and effectiveness of Tremelimumab for treating unresectable malignant mesothelioma, which could help improve future treatment options for this challenging condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, eligibility is confirmed based on specific criteria such as age, previous treatments, and health status.

    Written informed consent is required before any study-related procedures begin.

  2. Step 2

    Randomization

    Participants are randomly assigned to receive either tremelimumab or a placebo. This process is double-blind, meaning neither the participant nor the study team knows which treatment is being administered.

  3. Step 3

    Treatment administration

    Tremelimumab is administered as a solution for infusion. The dosage and frequency are determined by the study protocol.

    Participants receiving the placebo will undergo the same infusion process without the active medication.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to assess health status, including clinical laboratory evaluations, electrocardiograms (ECGs), and vital signs.

    Adverse events and serious adverse events are recorded and evaluated for severity and potential relation to the treatment.

  5. Step 5

    Evaluation of outcomes

    The primary outcome measured is overall survival, defined as the time from randomization until death from any cause.

    Secondary outcomes include survival rate at 18 months, disease control rate, progression-free survival, and overall response rate.

  6. Step 6

    End of study

    The study is estimated to conclude by June 30, 2025, at which point all data will be analyzed to determine the effectiveness and safety of tremelimumab compared to placebo.

Who can join the trial?

11 criteria

  • The patient must have a confirmed diagnosis of **pleural or peritoneal malignant mesothelioma**. This means the disease is in the lining of the lungs or abdomen and cannot be removed by surgery.
  • Women who can have children and are sexually active with a male partner must use a very effective form of birth control for 28 days before starting the study treatment and continue for 6 months after the last dose.
  • Men who are not sterilized and are sexually active with a woman who can have children must use a very effective form of birth control from the first day of treatment until 90 days after the last dose.
  • The patient must be **18 years or older** at the time they agree to participate.
  • The patient must have an **ECOG Performance status** of 0-1, which means they are fully active or have some symptoms but can still do light work.
  • The patient must have had 1-2 previous treatments for advanced disease, including a first-line treatment with **pemetrexed** (a type of chemotherapy) combined with a **platinum agent** (another type of chemotherapy).
  • The patient must have recovered from any side effects of previous treatments.
  • The patient must have a disease that can be measured by doctors.
  • The patient must have adequate function of the **bone marrow**, **liver**, and **kidneys**.
  • The patient must test negative for **HIV** and **hepatitis A, B, and C**.
  • The patient must provide written informed consent, which means they agree to participate in the study and understand what it involves.

Who cannot join the trial?

10 criteria

  • Patients who have had another type of cancer in the past, unless it was a type that is not likely to come back.
  • Patients who have a serious infection that is not under control.
  • Patients who are pregnant or breastfeeding.
  • Patients who have a condition that affects their immune system, which is the body's defense system against illnesses.
  • Patients who are taking medications that weaken the immune system.
  • Patients who have had an organ transplant, like a kidney or liver transplant.
  • Patients who have a history of severe allergic reactions to similar treatments.
  • Patients who have a condition that affects the brain or nervous system.
  • Patients who have a heart condition that is not stable.
  • Patients who have a lung condition that is not stable.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Tremelimumab is a medication being studied for its potential to treat malignant mesothelioma, a type of cancer that affects the lining of the lungs or abdomen. It works by helping the immune system recognize and attack cancer cells. In this clinical trial, tremelimumab is being compared to a placebo to see if it can improve the survival of patients who have already received other treatments.

What is already known about the treatment

Tremelimumab – Tremelimumab is administered intravenously, meaning it is given directly into a vein through an injection. It is currently being studied in clinical trials for its effectiveness in treating unresectable pleural or peritoneal malignant mesothelioma, a type of cancer that affects the lining of the lungs or abdomen. The medication works by targeting and inhibiting a protein called CTLA-4, which is involved in regulating the immune system. By blocking this protein, tremelimumab helps to enhance the body's immune response against cancer cells. It is classified as an immune checkpoint inhibitor, a type of drug that helps the immune system recognize and attack cancer cells more effectively.

Investigated diseases

Unresectable Pleural or Peritoneal Malignant Mesothelioma – This is a type of cancer that affects the lining of the lungs (pleura) or the abdomen (peritoneum). It is termed "unresectable" because it cannot be removed completely through surgery. The disease is often linked to asbestos exposure and progresses as cancer cells grow and spread in the affected lining. Symptoms may include chest pain, shortness of breath, or abdominal swelling, depending on the location. As the disease advances, it can lead to more severe respiratory or digestive issues. The progression is typically slow, but it can vary based on individual factors.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-511841-20-00Protocol codeD4880C00003Estimated enrolment223 patientsSponsorAstraZeneca AB

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.